Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decode how Medicare reimbursements shape Encompass Health鈥檚 margins? Each 10-K easily tops 250 pages, packed with therapy-minute tables and payor-mix footnotes. Sifting for occupancy trends or new-hospital pipeline data is time-consuming鈥攁nd Form 4 insider activity can shift before you even finish reading.
Stock Titan鈥檚 AI solves that problem. Our platform delivers Encompass Health SEC filings explained simply: instant summaries that translate complex accounting into plain English, plus red-flag alerts for every Encompass Health 8-K material events explained. Whether you need the latest Encompass Health quarterly earnings report 10-Q filing or a deep dive into the Encompass Health annual report 10-K simplified, we surface the numbers that drive rehab capacity and Medicare revenue.
- AG真人官方-time feed: Get Encompass Health Form 4 insider transactions real-time and see which executives are buying or selling.
- AI-powered highlights: Instantly spot CMS rule changes, segment EBITDA, and debt covenants without combing through exhibits.
- Comprehensive coverage: From Encompass Health proxy statement executive compensation to shelf registrations, every filing type is here the moment EDGAR posts it.
Use cases professionals rely on:
- Monitor Encompass Health executive stock transactions Form 4 ahead of dividend announcements.
- Compare rehab unit margins quarter-over-quarter with our Encompass Health earnings report filing analysis.
- Stay ahead of acquisition news with automated alerts on fresh 8-Ks.
Stop skimming PDFs and start understanding Encompass Health SEC documents with AI. All filings, all insights鈥攄elivered when they matter.
On 4 Aug 2025, ONEOK, Inc. (OKE) filed a Form 8-K under Items 2.02 and 7.01 to furnish, rather than file, a news release covering its second-quarter 2025 operating results (quarter ended 30 Jun 2025). The company also affirmed its full-year 2025 financial guidance ranges. All quantitative details are contained in Exhibit 99.1, which is incorporated by reference but not reproduced in the filing text. No other material transactions, leadership changes or financial statements were reported. Because the information is furnished, it is not subject to Section 18 liability and will not be automatically incorporated into future Securities Act or Exchange Act filings.
Sprinklr, Inc. (CXM) 鈥� Form 144 filing dated 07/29/2025
Insider Ragy Thomas has filed a Form 144 indicating an intent to sell 1,435 common shares on or about 29 Jul 2025 through Morgan Stanley Smith Barney. At the 07/28/2025 closing price, the shares are valued at $13,429.73. The company has 142,831,141 shares outstanding; the proposed sale represents <0.01 % of shares outstanding and is therefore immaterial in size.
The filing also discloses recent insider activity: over the prior three months Thomas sold an aggregate 9,327,768 shares in four transactions, generating gross proceeds of roughly $73.1 million. These larger prior sales amount to about 6.5 % of the shares outstanding and may signal continued divestiture by a key insider.
Because Form 144 is only a notice of intent, execution is not guaranteed. Nonetheless, recurring sizable sales by a founder/executive can influence market sentiment, especially if not paired with offsetting purchases or public rationale.
Streeterville Capital LLC, Streeterville Management LLC and John M. Fife filed Amendment No. 1 to Schedule 13G regarding Garden Stage Ltd (Nasdaq: GSIW).
The amendment, dated 29 July 2025, states the reporting persons now hold 0 ordinary shares, equal to 0.0 % of the outstanding class. Their current powers are:
- Sole voting power: 0
- Shared voting power: 0
- Sole dispositive power: 0
- Shared dispositive power: 0
The filing confirms the group鈥檚 ownership has fallen below the 5 % threshold that triggers a Schedule 13G, signalling a complete exit from a previously reportable stake. The signatories certify the shares were not acquired or held to influence control of the issuer.
Issuer address: 201, 2/F, China Insurance Group Building, 141 Des Voeux Road Central, Hong Kong. CUSIP: G3730L107.
No financial results or transactional details accompany this disclosure.
Huntington Ingalls Industries (HII) filed an 8-K reporting a governance change under Item 5.02. Effective 29-Jul-2025, the Board elected Nick L. Stanage, former Chairman & CEO of Hexcel Corporation, as a director and increased the Board size from 12 to 13 members.
Stanage is assigned to the Audit Committee and the Governance & Policy Committee. He will receive an annual cash retainer of $120 k plus $25 k (Audit) and $20 k (Governance) committee fees, and an annual equity grant of $165 k in deferred stock units, all prorated for 2025.
No financial results, strategic transactions, or other material events were disclosed.
FAQ
What is the current stock price of Encompass Health (EHC)?
What is the market cap of Encompass Health (EHC)?
What is the primary focus of Encompass Health Corp?
How does Encompass Health generate its revenue?
What innovative practices differentiate Encompass Health?
What types of care does Encompass Health offer?
How does the company maintain high-quality care?
What regions does Encompass Health primarily serve?
How is Encompass Health positioned within the healthcare industry?
How does Encompass Health support operational efficiency?
